Overview Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) Status: Recruiting Trial end date: 2022-11-01 Target enrollment: Participant gender: Summary This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema). Phase: Phase 3 Details Lead Sponsor: Arcutis Biotherapeutics, Inc.